Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial
Related Posts
Neilsen BK, Huang RR, Valle LF, Proudfoot JA, Davicioni E, Zhang L, Ryg U, Schulz-Jaavall M, Weidhaas JB, Santoso M, Parmisano S, Calais J, Reiter[...]
Talishinsky A, Bachour K, Lin C, Zakka P, Bassam K, Bull L, Garon E, Krokhaleva Y, Hanna P, Yang EH. Immune Checkpoint Inhibitor Myocarditis Masquerading[...]
Janjigian YY, Oh DY, Pelster M, Wainberg ZA, Prusty S, Nelson S, DuPage A, Thompson A, Koralek DO, Sison EAR, Rha SY. Domvanalimab and zimberelimab[...]